MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote
- BSE Healthcare
- Top Losers Today
Top Losers Today 
:
BSE Healthcare
Here are the top top losers today from the BSE Healthcare index. To know more about the Index, please visit the BSE Healthcare Live Chart. Also read our detailed report on the pharmaceuticals sector.
Date: Nov 27, 2020 (Close)
Tomorrow at 5pm: Get the details of India's #1 defence stock
| COMPANY | PRICE (Rs) | CHANGE (%) | VOLUME ('000) | DAY'S H/L (Rs) | 52-WEEK H/L (Rs) | GET MORE INFO |
|---|---|---|---|---|---|---|
| S&P BSE SENSEX | 44,149.72 | -0.3% | - |
44,407 / 43,995 |
44,825 / 25,639 |
More Info
|
| NIFTY 50 | 12,968.95 | -0.1% | - |
13,035 / 12,914 |
13,146 / 7,511 |
More Info
|
| S&P BSE HEALTHCARE | 20,318.54 | 1.0% | - |
20,425 / 20,149 |
20,689 / 10,948 |
More Info
|
| FERMENTA BIOTECH | 301.30 | -2.9% | 51.4 | 316 / 300 | 442 / 151 | More Info
|
| PIRAMAL ENTERPRISES | 1,386.70 | -2.6% | 26.4 | 1,442 / 1,376 | 1,814 / 608 | More Info
|
| UNICHEM LAB | 255.50 | -2.3% | 5.2 | 260 / 254 | 304 / 75 | More Info
|
| DR. REDDYS LAB | 4,829.60 | -1.4% | 34.2 | 4,935 / 4,811 | 5,515 / 2,498 | More Info
|
| SHALBY | 105.10 | -1.4% | 3.0 | 109 / 105 | 121 / 40 | More Info
|
| INDOCO REMEDIES | 261.30 | -1.3% | 11.2 | 270 / 260 | 295 / 145 | More Info
|
| SUVEN LIFESCIENCES | 46.50 | -1.1% | 53.7 | 48 / 46 | 322 / 19 | More Info
|
| VIVIMED LABS | 17.10 | -0.9% | 23.1 | 18 / 17 | 24 / 7 | More Info
|
| LUPIN | 891.80 | -0.9% | 117.5 | 914 / 890 | 1,122 / 505 | More Info
|
| NOVARTIS | 652.00 | -0.6% | 2.1 | 662 / 651 | 742 / 420 | More Info
|
| INDRAPRASTHA MEDICAL | 51.65 | -0.6% | 16.5 | 53 / 51 | 65 / 27 | More Info
|
| PFIZER | 5,104.10 | -0.3% | 4.6 | 5,121 / 5,081 | 5,875 / 3,588 | More Info
|
| AUROBINDO PHARMA | 868.05 | -0.3% | 118.9 | 893 / 865 | 968 / 281 | More Info
|
| HEALTHCARE GLOBAL ENTER. | 147.90 | -0.3% | 3.3 | 148 / 145 | 150 / 63 | More Info
|
| MEDICAMEN BI | 408.10 | -0.2% | 4.3 | 415 / 390 | 525 / 153 | More Info
|
| SANOFI INDIA | 8,235.35 | -0.2% | 11.4 | 8,348 / 8,050 | 8,999 / 5,900 | More Info
|
| TORRENT PHARMA | 2,611.10 | -0.2% | 22.2 | 2,679 / 2,591 | 3,040 / 1,619 | More Info
|
| ERIS LIFESCIENCES LIMITED | 522.15 | -0.2% | 2.0 | 525 / 514 | 593 / 341 | More Info
|
| MOREPEN LABS | 29.35 | -0.2% | 209.7 | 30 / 29 | 35 / 7 | More Info
|
| DISHMAN CARBOGEN AMCIS | 144.70 | -0.1% | 30.8 | 147 / 144 | 217 / 46 | More Info
|
| GRANULES INDIA | 412.45 | -0.1% | 49.5 | 418 / 408 | 425 / 115 | More Info
|
| SUN PHARMA | 511.55 | -0.0% | 224.6 | 521 / 510 | 565 / 315 | More Info
|
Only Buyers
Only Sellers * Mutual Funds that hold this stock
What else is happening in the markets today? Dig in...
- TRACK NOW:
- Most Active Stocks Rs 0 to 10
- Most Active Stocks Rs 10 to 20
- Top Gainers Today BSE A Group
- Top Gainers Today NSE Above Rs 20
- Top Gainers Today BSE Above Rs 20
- Top Gainers Today BSE Sensex
- Top Gainers Today BSE Small Cap
- Top Gainers Today BSE 500
- Top Losers Today BSE A Group
- Most Active Stocks Rs 1 to 2
- Top Losers Today NSE Above Rs 20
- Buzzing Stocks Today
- Most Popular Stocks BSE 30
- TRENDING ON EQUITYMASTER:
- Warren Buffett - The Value Investor
- Your Ultimate Guide to Penny Stock Investing
- How to Invest in Gold
- Basics of Value Investing
- Benjamin Graham
- The Best Bluechip Stocks to Buy
- How to Invest in Silver
- The Best Small-cap Stocks to Buy
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Best Stocks to Buy Today
Today's Market
Sensex Ends 110 Points Lower; Smallcap & Midcap Stocks Outperform(Closing)
Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower, ahead of Q2 GDP data.
Related Views on News
PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY21); Net Profit Up 22.1% (Quarterly Result Update)
Aug 25, 2020 | Updated on Aug 25, 2020For the quarter ended June 2020, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 22.1% YoY). Sales on the other hand came in at Rs 29 bn (down 16.2% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.
PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY20); Net Profit Up 11.7% (Quarterly Result Update)
Feb 5, 2020 | Updated on Feb 5, 2020For the quarter ended December 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 11.7% YoY). Sales on the other hand came in at Rs 38 bn (up 9.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.
PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)
Jul 9, 2019 | Updated on Jul 9, 2019Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.
UNICHEM LAB 2018-19 Annual Report Analysis (Annual Result Update)
Jul 4, 2019 | Updated on Jul 4, 2019Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.
More Views on NewsMost Popular
Not Infosys or Wipro. India's Next Wealth Creators Could Be Drone Stocks (Profit Hunter)
Nov 25, 2020India's drones directorate signals the next big defence tech multibaggers.
Stocks that Could Shine More than Gold After Diwali (Profit Hunter)
Nov 17, 2020If the markets become volatile over the next few months, do this.
How the New Margins Will Impact You (Fast Profits Daily)
Nov 25, 2020The new rules on margins will come into effect from 1st December. Are you ready?
How to Build the Best Trading System (Fast Profits Daily)
Nov 20, 2020In this video, I'll show you how to make the best trading system.
An Eraser and Some Pencils (The Honest Truth)
Nov 17, 2020Ajit Dayal on the road ahead for the world after covid.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
S&P BSE HEALTHCARE
Nov 27, 2020 (Close)
S&P BSE HEALTHCARE 5-YR ANALYSIS
COMPARE COMPANY
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.